Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Nonmelanoma skin cancer, primarily comprising basal cell carcinoma and cutaneous squamous cell carcinoma, represents one of the most common malignancies worldwide and a growing public health concern. According to GLOBOCAN 2022 estimates, nonmelanoma skin cancers were the fifth most common cancer globally, with approximately 1,234,533 new cases and around 69,416 deaths reported worldwide in that year. Its prevalence continues to rise, particularly among aging populations and regions with high ultraviolet exposure, contributing to a substantial healthcare burden despite relatively low mortality. The nonmelanoma skin cancer pipeline analysis by Expert Market Research highlights continued innovation across targeted and immunotherapeutic approaches aimed at improving long-term disease control.
-
Major companies involved in the nonmelanoma skin cancer pipeline analysis include AstraZeneca, KaliVir Immunotherapeutics, and others.
-
Leading drugs currently in the pipeline include N17350, AZD6750, and others.
-
The pipeline is driven by the rising incidence of advanced basal and squamous cell carcinomas, increasing adoption of immunotherapies such as cemiplimab, and innovations in targeted and topical therapies. Novel gene-based and polymer-based treatments are accelerating development, expanding therapeutic options for patients unsuitable for conventional surgery or radiotherapy.
Report Coverage
The Nonmelanoma Skin Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into nonmelanoma skin cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for nonmelanoma skin cancer. The nonmelanoma skin cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The nonmelanoma skin cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with nonmelanoma skin cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to nonmelanoma skin cancer.
Read more about this report - Request a Free Sample
Nonmelanoma Skin Cancer Pipeline Outlook
Nonmelanoma skin cancer (NMSC), predominantly basal cell carcinoma and cutaneous squamous cell carcinoma (CSCC), is typically managed with surgical excision, radiotherapy. For advanced disease, systemic therapies such as hedgehog inhibitors and immune checkpoint inhibitors are commonly employed. The pipeline continues to prioritize targeted and immunotherapeutic approaches to improve outcomes and reduce recurrence.
Nonmelanoma skin cancer treatment has recently advanced with the October 2025 FDA approval of cemiplimab-rwlc (Libtayo) as an adjuvant treatment for adults with high-risk CSCC following surgery and radiotherapy, aimed at lowering the risk of disease recurrence. Emerging agents in trials seek enhanced efficacy with favorable safety profiles.
Nonmelanoma Skin Cancer Epidemiology
Nonmelanoma skin cancers, primarily basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), are among the most frequently diagnosed cancers worldwide. According to GLOBOCAN 2022, there were an estimated 1.23 million new NMSC cases and about 69,000 deaths globally in that year, ranking NMSC fifth in overall cancer incidence. Incidence is highest in high-income regions such as Australasia, North America and Europe, driven by ultraviolet exposure and aging populations, while rates in Asia and Africa remain lower. The burden continues to increase with demographic shifts and enhanced detection.
Nonmelanoma Skin Cancer – Pipeline Therapeutic Assessment
This section of the report covers the analysis of nonmelanoma skin cancer drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The nonmelanoma skin cancer pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
- Polymers
- Gene Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Nonmelanoma Skin Cancer Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total nonmelanoma skin cancer clinical trials. The phase 1 covers 29%, phase 2 accounts for 43%, and phase 3 covers 24% drugs, providing an in-depth analysis of each.
Nonmelanoma Skin Cancer Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the nonmelanoma skin cancer pipeline analysis include monoclonal antibodies, small molecules, peptides, polymers, and gene therapies. The nonmelanoma skin cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for nonmelanoma skin cancer. In December 2024, the FDA approved cosibelimab-ipdl (Unloxcyt) for adults with advanced cutaneous squamous cell carcinoma that is locally advanced or metastatic and not suitable for curative surgery or radiotherapy.
Nonmelanoma Skin Cancer Clinical Trials – Key Players
The EMR report for the nonmelanoma skin cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed nonmelanoma skin cancer therapeutic assessment, analysing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in nonmelanoma skin cancer clinical trials:
- Phio Pharmaceuticals Inc.
- Onchilles Pharma Inc
- AstraZeneca
- KaliVir Immunotherapeutics
- Regeneron Pharmaceuticals
- Stamford Pharmaceuticals, Inc.
- Sirnaomics
- AiViva BioPharma, Inc.
- Feldan Therapeutics
- Verrica Pharmaceuticals Inc.
Nonmelanoma Skin Cancer – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for nonmelanoma skin cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of nonmelanoma skin cancer drug candidates.
Drug: N17350
N17350 is an engineered tumor‑directed cytotoxic biologic utilising the ELANE pathway to selectively kill cancer cells while sparing healthy tissue and activating systemic immune responses. It induces immunogenic cell death and shows potent anti‑tumor efficacy in preclinical models of diverse solid tumors, including skin cancers. Onchilles Pharma, a biotechnology company pioneering next‑generation cytotoxic therapies, is advancing N17350 toward first‑in‑human trials, supported by extensive translational data and recent financing to propel clinical development. The study is anticipated to be completed on November 2029.
Drug: AZD6750
AZD6750 is a novel CD8‑guided interleukin‑2 (IL‑2) agent being evaluated for safety, pharmacokinetics and efficacy in advanced or metastatic solid tumors, including cutaneous squamous cell carcinoma (a form of nonmelanoma skin cancer). It may be administered alone or with other anticancer agents to stimulate immune‑mediated tumor control. AstraZeneca, a global biopharmaceutical leader in oncology, is conducting this Phase 1/2 clinical study as part of its broad immuno‑oncology pipeline. The study is expected to be completed by February 2029.
Drug: MQ710
MQ710 is an investigational biological therapeutic being assessed in early‑phase clinical trials as part of combination immuno‑oncology regimens for solid tumors, including basal cell carcinoma and other skin cancers. It functions by leveraging modified viral vectors or transgene expression mechanisms to enhance anti‑tumor immune activity in conjunction with immune checkpoint inhibitors such as pembrolizumab. This trial is sponsored by the Memorial Sloan Kettering Cancer Center and targets a range of solid tumor types where conventional therapies have failed. The study is likely to be completed by May 2028.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Nonmelanoma Skin Cancer Pipeline Insight Report
- Which companies/institutions are leading the nonmelanoma skin cancer drug development?
- Which company is leading the nonmelanoma skin cancer pipeline development activities?
- What is the current nonmelanoma skin cancer commercial assessment?
- What are the opportunities and challenges present in the nonmelanoma skin cancer pipeline landscape?
- What is the efficacy and safety profile of nonmelanoma skin cancer pipeline drugs?
- Which company is conducting major trials for nonmelanoma skin cancer drugs?
- Which companies/institutions are involved in nonmelanoma skin cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in nonmelanoma skin cancer?
Reasons To Buy This Report
The Nonmelanoma Skin Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for nonmelanoma skin cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into nonmelanoma skin cancer collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share